Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation

  • B. Lubec
  • B. C. Yoo
  • M. Dierssen
  • N. Balic
  • G. Lubec


Apoptosis has been implicated in the selective neuronal loss of Down syndrome (DS). Apoptosis activates a family of cysteine proteases with specificity for aspartic acid residues referred to as caspases that play a key role in dismantling a cell committed to die. Caspase activity is regulated by a variety of proteins that possess a domain resembling the prodomains of caspases. Little is known, however, about the changes of caspases and their regulatory proteins in DS. Here, we investigated levels of nine such different proteins by western blot technique in frontal cortex and cerebellum of control and DS subjects. The protein levels of DFF45 (DNA fragmentation factor 45), and FLIP (FADD like interleukin-lß-converting enzyme inhibitory proteins) were significantly decreased whereas that of RICK (RIP-like interacting CLARP kinase) increased in both regions of DS. In contrast, cytochrome c, Apaf-1 (apoptosis protease activating factor-1), procaspase-9 and ARC (apoptosis repressor with caspase recruitment domain) were unchanged. Procaspase-3 and -8 were significantly decreased in frontal cortex but no significant change was observed in cerebellum. Regression analysis revealed no correlation between postmortem interval and levels of the investigated proteins. However, inconsistent correlation was found between age and levels of proteins as well as amongst the density of individual proteins. These findings demonstrate that dysregulation of apoptotic proteins does exist in DS brain and may underlie the neuropathology of DS. The study further suggests that apoptosis in DS may occur via the death receptor pathway independent of cytochrome c. Hence, therapeutic strategies that target caspase activation may prove useful in combating neuronal loss in this disorder.


Tyrosine Hydroxylase Down Syndrome Neuronal Density Cholinergic Innervation Down Syndrome Patient 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arenander AT, de Vellis J (1982) Glial-released proteins in neural intercellular communication: molecular mapping, modulation, and influence on neuronal differentiation. Prog Clin Biol Res 79: 243–269PubMedGoogle Scholar
  2. Brooksbank BW, Walker D, Balazs R, Jorgensen OS (1989) Neuronal maturation in the foetal brain in Down’s syndrome. Early Hum Dev 18: 237–246PubMedCrossRefGoogle Scholar
  3. Candy JM, Perry EK, Perry RH, Bloxham CA, Thompson J, Johnson M, Oakley AE, Edwardson JA (1985) Evidence for the early prenatal development of cortical cholinergic afferents from the nucleus of Meynert in the human foetus. Neurosci Lett 61: 91–95PubMedCrossRefGoogle Scholar
  4. Catravas GN, Takenaga J, McHale CG (1977) Effect of chronic administration of morphine on monoamine oxidase activity in discrete regions of the brain of rats. Biochem Pharmacol 26: 211–214PubMedCrossRefGoogle Scholar
  5. De la Monte SM (1999) Molecular abnormalities of the brain in Down syndrome: relevance to Alzheimer’s neurodegeneration. J Neural Transm [Suppl] 57: 1–19Google Scholar
  6. Goelet P, Castellucci VF, Schacher S, Kandel ER (1986) The long and the short of longterm memory-a molecular framework. Nature 322: 419–422PubMedCrossRefGoogle Scholar
  7. Gulesserian T, Engidawork E, Cairns N, Lubec G (2000) Increased protein levels of serotonin transporter in frontal cortex of patients with Down syndrome. Neurosci Lett 296: 53–57PubMedCrossRefGoogle Scholar
  8. Hamon M, Bourgoin S, Chanez C, De Vitry F (1989) Do serotonin and other neurotransmitters exert a trophic influence on the immature brain? In: Evrard P, Minkowski A (eds) Nestle nutrition workshop series: developmental neurobiology. Raven Press, New York, pp 171–183Google Scholar
  9. Hansson SR, Hoffman BJ, Mezey E (1998) Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system. Brain Res Dev Brain Res 110: 135–158PubMedCrossRefGoogle Scholar
  10. Hoffman BJ, Hansson SR, Mezey E, Palkovits M (1998) Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol 19: 187–231PubMedCrossRefGoogle Scholar
  11. Ivgy-May N, Tamir H, Gershon MD (1994) Synaptic properties of serotonergic growth cones in developing rat brain. J Neurosci 14: 1011–1029PubMedGoogle Scholar
  12. Kish S, Karlinsky H, Becker L, Gilbert J, Rebbetoy M, Chang LJ, DiStefano L, Hornykiewicz O (1989) Down’s syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem 52: 1183–1187PubMedCrossRefGoogle Scholar
  13. Lane NJ, Balbo A, Rapoport SI (1996) A fine structural study of the hippocampus and dorsal root ganglion in mouse trisomy 16, a model of Down’s syndrome. Cell Biol Int 20: 673–680PubMedCrossRefGoogle Scholar
  14. Lauder JM (1990) Ontogeny of the serotonergic system in the rat: serotonin as a developmental signal. Ann NY Acad Sci 600: 297–314PubMedCrossRefGoogle Scholar
  15. Lipton SA, Kater SB (1989) Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. Trends Neurosci 12: 265–270PubMedCrossRefGoogle Scholar
  16. Malamud N (1972) Neuropathology of organic brain sydromes associated with aging. In: Gartz CM (ed) Aging and the brain. Nestec Ltd., Vevey; Raven Press, New York, p 63CrossRefGoogle Scholar
  17. Mattson MP (1998) Neurotransmitters in the regulation of neuronal cytoarchitecture. Brain Res 472: 179–212Google Scholar
  18. Perry EK, Smith CJ, Atack JR, Candy JM, Johnson M, Perry RH (1986) Neocortical cholinergic enzyme and receptor activities in the human fetal brain. J Neurochem 47: 1262–1269PubMedCrossRefGoogle Scholar
  19. Risser D, Lubec G, Cairns N, Herrera-Marschitz M (1997) Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 60: 1231–1237PubMedCrossRefGoogle Scholar
  20. Sacks B, Smith S (1989) People with Down’s syndrome can be distinguished on the basis of cholinergic dysfunction. J Neurol Neurosurg Psychiatry 52: 1294–1295PubMedCrossRefGoogle Scholar
  21. Schafer MK, Weihe E, Varoqui H, Eiden LE, Erickson JD (1994) Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat. J Mol Neurosci 5: 1–26PubMedCrossRefGoogle Scholar
  22. Schapiro MB, Kay AD, May C, Ryker AK, Haxby JV, Kaufman S, Milstien S, Rapoport SI (1987) Cerebrospinal fluid monoamines in Down’s syndrome adults at different ages. J Ment Deflc Res 31: 259–269Google Scholar
  23. Seidl R, Kaehler ST, Prast H, Singewald N, Cairns N, Gratzer M, Lubec G (1999) Serotonin (5-HT) in brains of adult patients with Down syndrome. J Neural Transm [Suppl] 57: 221–232Google Scholar
  24. Shen WZ, Luo ZB, Zheng DR, Yew DT (1989) Immunohistochemical studies on the development of 5-HT (serotonin) neurons in the nuclei of the reticular formations of human fetuses. Pediatr Neurosci 15: 291–295PubMedCrossRefGoogle Scholar
  25. Sundstrom E, Kolare S, Souverbie F, Samuelsson EB, Pschera H, Lunell NO, Seiger A (1993) Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Brain Res Dev Brain Res 75: 1–12PubMedCrossRefGoogle Scholar
  26. Takashima S, Becker LE, Armstrong DL, Chan F (1981) Abnormal neuronal development in the visual cortex of the human fetus and infant with down’s syndrome. A quantitative and qualitative Golgi study. Brain Res 225: 1–21PubMedCrossRefGoogle Scholar
  27. Yew DT, Chan WY (1999) Early appearance of acetylcholinergic, serotoninergic, and peptidergic neurons and fibers in the developing human central nervous system.Microsc Res Tech 45: 389–400PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2001

Authors and Affiliations

  • B. Lubec
    • 1
  • B. C. Yoo
    • 2
  • M. Dierssen
    • 3
  • N. Balic
    • 4
  • G. Lubec
    • 2
  1. 1.Department of NeonatologyUniversity of ViennaViennaAustria
  2. 2.Department of PediatricsUniversity of ViennaViennaAustria
  3. 3.Medical and Molecular Genetics Center-IROHospital Duran i ReynalsBarcelonaSpain
  4. 4.Institute of Medical and Chemical Laboratory DiagnosticsUniversity of ViennaViennaAustria

Personalised recommendations